Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women

Clinical Genetics

Volumn 72, Issue 2, 2007, Pages 87-97

  Apicella, C ^a   Dowty, J G ^a   Dite, G S ^a   Jenkins, M A ^a   Senie, R T ^b   Daly, M B ^c   Andrulis, I L ^d,e   John, E M ^f   Buys, S S ^g   Li, F P ^h   Glendon, G ^d   Chung, W ^b   Ozcelik, H ^e   Miron, A ^g   Kotar, K ⁱ   Southey, M C ^a   Foulkes, W D ⁱ   Hopper, John L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Columbia University ^*  (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d CANCER CARE ONTARIO   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f NORTHERN CALIFORNIA CANCER CENTER   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

Author keywords

Ashkenazi Jewish; BRCA1; BRCA2; Breast cancer; Mutations; Ovarian

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOSINE; GUANINE;

ACCURACY; ADULT; ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILY HISTORY; GENE DELETION; GENE INSERTION; GENE MUTATION; HETEROZYGOTE; HUMAN; JEW; NORTH AMERICA; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; VALIDATION STUDY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE DETECTION; HUMANS; JEWS; LOGISTIC MODELS; MIDDLE AGED; MODELS, STATISTICAL; MUTATION; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 34547876552     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00841.x     Document Type: Article

References (43)

1. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999: 64: 963-970.
2. Robson M, Dabney MK, Rosenthal G et al. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genet Test 1997: 1: 47-51.
3. Fodor FH, Weston A, Bleiweiss IJ et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998: 63: 45-51.
4. Fitzgerald MG, MacDonald DJ, Krainer M et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996: 334: 143-149.
5. Moslehi R, Chu W, Karlan B et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000: 66: 1259-1272.
6. Levy-Lahad E, Catane R, Eisenberg S et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997: 60: 1059-1067.
7. Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997: 60: 505-514.
8. Warner E, Foulkes W, Goodwin P et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999: 91: 1241-1247.
9. James P, Doherty R, Harris M et al. Optimal selection of individuals for BRCA mutation testing: A comparison of available methods. J Clin Oncol 2006: 24: 707-715.
10. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004: 23: 1111-1130.
11. Evans DG, Eccles DM, Rahman N et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004: 41: 474-480.
12. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004: 91: 1580-1590.
13. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997: 336: 1401-1408.
14. Antoniou AC, Pharoah PDP, Narod S et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: A combined analysis of 22 population based studies. J Med Genet 2005: 42: 602-603.
15. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998: 62: 145-158.
16. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997: 278: 1242-1250.
17. Couch FJ, DeShano ML, Blackwood A et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Eng J Med 1997: 336: 1409-1415.
18. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 2002: 20: 1480-1490.
19. Apicella C, Andrews L, Hodgson SV et al. An algorithm for estimating the Log odds of the probability of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family cancer history in an Ashkenazi Jewish woman (LAMBDA). Breast Cancer Res 2003: 5: R206-R216.
20. Hopper JL, Jenkins MA. Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2. Am J Hum Genet 1999: 65: 1771-1775.
21. John EM, Hopper JL, Beck JC. et al. Breast Cancer Family Registry. The Breast Cancer Family Registry: An infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004: 6 (4): R375-R389.
22. Kotar K, Brunet JS, Moller P et al. Ratio of female to male offspring of women tested for BRCA1 and BRCA2 mutations. J Med Genet 2004: 41: e103.
23. Özçelik H, Antebi Y, Cole DEC, Andrulis IL. Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation. Hum Genet 1996: 98: 310-312.
24. Yazici H, Bitisik O, Akisik E et al. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000: 83: 737-742.
25. Li D, Vijg J. Multiplex co-amplification of 24 retinoblastoma gene exons after pre-amplification by long-distance PCR. Nucleic Acids Res 1996: 24: 538-539.
26. Van Orsouw NJ, Li D, van der Vlies P et al. Mutational scanning of large genes by extensive PCR multiplexing and two-dimensional electrophoresis: application to the RB1 gene. Hum Mol Genet 1996: 5: 755-761.
27. Miron A, Schildkraut JM, Rimer BK et al. Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg 2000: 231: 624-634.
28. Andrulis IL, Anton-Culver H, Bove B et al. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 2003: 20: 65-73.
29. Chen S, Iversen ES, Friebel T et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006: 24: 863-871.
30. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating curves: A nonparametric approach. Biometrics 1988: 44: 837-845.
31. Cox DR, Snell EJ. Analysis of binary data, 2nd edn. London: Chapman & Hall, 1989.
32. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2005; ISBN 3-900051-07-0, from URL http://www.R-project.org
33. Berry DA, Iversen ES Jr, Gudbjartsson DF et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002: 20: 2701-2712.
34. Euhus DM, Smith KC, Robinson L et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002: 94: 844-851.
35. Antoniou A, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006: 1: 257-274.
36. Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003: 95: 1482-1485.
37. Lakhani SR, Reis-Filho JS, Fulford L. et al.; Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005: 11: 5175-5180.
38. Bane AL, Beck JC, Bleiweiss I et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007: 31: 121-128.
39. King MC, Marks JH, Mandell JB.; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003: 302: 643-646.
40. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for BRCA1/2 carriers. Science 2004: 306: 2187-2191.
41. Easton DF, Hopper JL, Thomas DC et al. Breast cancer risks for BRCA1/2 carriers. Science 2004: 306: 2187-2191.
42. Tesoriero A, Andersen C, Southey M et al. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 1999: 65: 567-569.
43. van der Luijt RB, van Zon PHA, Jansen MPM, van der Sijs-Bos CJM, Wárlám-Rodenhuis CC, Ausems MGEM. De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet 2001: 38: 102-105.